GnRH Antagonist to Prepare Recipients for Embryo Transfer
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
26% of all ART cycles performed in the USA in 2003 (CDC data) are frozen embryo transfers
(FET) and transfer of embryos resulting from egg donation (ED) to recipients. The typical
protocol used to prepare a recipient for ET involves GnRH agonist (Lupron, Tap
Pharmaceuticals) to down regulate the patient. A GnRH antagonist, such as Cetrotide (EMD
Serono), is comparable to GnRH agonist and FDA approved to prevent spontaneous ovulation with
ART treatment, and its usage decreases significantly the number of injections that the
patient receives with treatment. The working hypothesis for this study is that the GnRH
antagonist (Cetrotide) can be used instead of an agonist to achieve effective down regulation
in FET and ED cycles. Presumably, patients will prefer Cetrotide over Lupron because of the
markedly fewer injections required.